Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WhiskerBlock Alpha is a bioengineered protein technology developed by Pacagen that utilizes single-domain antibodies (sdAbs) to neutralize Fel d 1, the primary protein responsible for cat allergies. The technology is available in two consumer formats: a neutralizing spray for environmental surfaces and an oral supplement (food topper) for cats. By binding to Fel d 1 at the source or in the environment, WhiskerBlock Alpha inactivates the allergen before it can trigger allergic symptoms in humans. It is marketed as a safe, food-grade consumer product rather than a pharmaceutical drug, designed to reduce environmental cat allergen exposure by up to 98%.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WhiskerBlock Alpha.